Teri Schwarz, MD
Psychiatry · Metairie, LANPI 1487707972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 741 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,654 and has fallen 60.1% since, to $1,058 in 2025. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 741 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$1K
- Johnson & Johnson$878
- Takeda Pharmaceuticals U.S.A., Inc.$877
- plus $6K from 27 others
What the payments were for
- Food & beverage$12,544100%
- Education$460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $1,871 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,190 |
| Alkermes, Inc. | 58 | $1,150 |
| Lundbeck LLC | 67 | $1,110 |
| Johnson & Johnson | 52 | $878 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $877 |
| Sunovion Pharmaceuticals Inc. | 45 | $839 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $632 |
| Teva Pharmaceuticals USA, Inc. | 38 | $570 |
| Supernus Pharmaceuticals, Inc. | 16 | $368 |
| Tris Pharma Inc | 16 | $297 |
| Almatica Pharma LLC | 14 | $276 |
| Vanda Pharmaceuticals Inc. | 15 | $275 |
| Noven Therapeutics, LLC | 14 | $241 |
| Corium, LLC | 12 | $228 |
| Axsome Therapeutics, Inc. | 12 | $217 |
| Merck | 13 | $203 |
| Jazz Pharmaceuticals Inc. | 9 | $194 |
| Bausch Health US, LLC | 8 | $159 |
| Indivior Inc. | 10 | $158 |
| Neurocrine Biosciences, Inc. | 7 | $152 |
| Shire North American Group Inc | 9 | $147 |
| Idorsia Pharmaceuticals US Inc | 8 | $135 |
| Eisai Inc. | 8 | $123 |
| Neos Therapeutics, LP | 5 | $94 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Neuronetics, Inc. | 3 | $45 |
| Adlon Therapeutics L.p. | 3 | $38 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| Brainsway USA Inc | 1 | $10 |
How this compares
$12,589 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 25 | $155,997 |
| VraylarCariprazine Hcl | 40 | $95,327 |
| RexultiBrexpiprazole | 17 | $36,621 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 294 | $10,668 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $7,255 |
| Aripiprazole | 132 | $5,419 |
| Ziprasidone Hcl | 49 | $4,683 |
| Bupropion XlBupropion Hcl | 133 | $3,330 |
| Olanzapine | 166 | $3,228 |
| Duloxetine Hcl | 141 | $3,116 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 124 | $2,794 |
| Fluoxetine Hcl | 230 | $2,592 |
| Clonazepam | 276 | $2,586 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $2,468 |
| Doxepin Hcl | 57 | $2,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $570 | $155,99725 claims |
| AbbVieVraylar | $1,871 | $95,32740 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,190 | $36,62117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $877 | $7,25515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Metairie
- Charles ChesterMetairie$14K
- Julie CeasarMetairie$12K
- Kenneth SumnerMetairie$12K
- Jonathon RynningMetairie$11K
- Sidney SmithMetairie$10K
- Jose RodriguezMetairie$9K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Larry WarnerBaton Rouge$495K
- Gregory BrownShreveport$495K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.